Prolexys Licenses the Prolexys Human Interactome Database to GlaxoSmithKline
Complete the form below to unlock access to ALL audio articles.
Prolexys Pharmaceuticals, Inc. has announced that it has completed a non-exclusive license agreement with GlaxoSmithKline for the Prolexys Human Interactome Database.
This database contains over 258,000 human protein-protein interactions, representing approximately one half of all RefSeq entries.
The dataset was built from a wide range of human cell and tissue types using the Company's HyNet™ system, a highly automated high-throughput yeast 2-hybrid process.
This system is designed to give a strong preference to high confidence interactions and the quality of the data has been demonstrated in a variety of tests.
“This asset adds significant value to state-of-the-art pharmaceutical research programs in the areas of novel target identification, target validation, improved understanding of disease biology, and efficient choice of research direction,” said Dr. Sudhir Sahasrabudhe, Chief Scientific Officer of Prolexys.
